MAM
Indian martech company Infloso unveils “Molly”
Mumbai: Infloso, an Indian marketing tech company with over 1 million global users, has introduced the world’s first AI marketer “Molly”. This groundbreaking AI—capable of handling end-to-end marketing campaigns independently with precision and swiftness—is set to disrupt the global marketing industry, potentially replacing several marketing jobs.
Molly is a supercharged AI marketer that tirelessly trains itself on a brand’s entire digital footprint across the internet, and leverages real-time data intelligence to drive efficient, ROI-driven campaigns. It harnesses cutting-edge machine learning techniques, such as Latent Semantic Indexing (LSI) to analyse a massive dataset of over 1 billion data points, ensuring the most comprehensive brand analysis in the industry. Additionally, Molly employs Convolutional Neural Networks (CNNs) for Image and Video Analysis to optimise visual content understanding and to extract actionable insights, combined with Predictive Analytics to forecast and fine-tune campaign performance. With its ability to autonomously optimise campaigns based on real-time performance metrics and market dynamics, Molly not only continuously elevates campaign efficiency but also enhances user control, allowing brands to integrate video, sales data, and customer insights to further amplify its capabilities.
In its official unveiling video, Molly showcases its ability to execute several tasks traditionally demanding significant human efforts and bandwidth. The video includes the demonstration of an earphone launch strategy—identifying the optimal date and market and conducting a competitive analysis for the launch. In another example, Molly analyses a drop in daily sales and pinpoints the cause—a loading error on the billing page—leading to 119 customer dropouts. Beyond these examples, Molly’s capabilities extend to growing social media channels, optimising content strategies, launching new marketing initiatives, auditing websites, elevating online reputation, budgeting campaigns, and much more, all with unparalleled efficiency and precision.
In its debut version, Molly is equipped with the powerful capability to comprehend and analyse data in 8 major languages: English, Hindi, German, Italian, French, Russian, Chinese, and Spanish. Infloso is committed to pushing boundaries, with plans to significantly expand Molly’s linguistic proficiency in future iterations. The anticipation surrounding the AI Marketer has already sparked tremendous interest, with CMOs, brand managers, marketing managers, analysts, D2C & SaaS founders, and agency owners eagerly joining the waitlist at http://molly.infloso.ai/. With the waitlist now open to all, the momentum is swiftly accelerating, as more industry leaders rush to be a part of this revolutionary AI tool. The waitlist has already seen over 5,000 registrations within days.
Speaking on Molly’s unveiling, Infloso’s founder Utkarsh Khandelwal said, “Molly is well positioned to disrupt the marketing landscape, reducing brands’ dependencies on external partners, and empowering marketers. It is much faster and more efficient in doing the work that brands have traditionally relied on agencies for, coupled with better transparency and diligence. For example, an end-to-end campaign which marketing teams would typically take 7-10 days to strategise and execute, can be concluded by Molly in merely a couple of minutes — with significantly higher precision. Furthermore, founders have always had a tough time translating their vision into marketing and getting the right fit with an agency. With Molly, they can benefit with complete autonomy and control.”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
